

## Pharmacy Prior Authorization Form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to: ☐ Commercial (Traditional) ☐ Commercial (Individual/Optimized)

☒ **Medicaid**

This request is: ☐ **Urgent** (life threatening) ☐ **Non-Urgent** (standard review)

Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

## Pulmozyme<sup>®</sup> (dornase alfa)

### Member

Last Name: \_\_\_\_\_

First Name: \_\_\_\_\_

ID #: \_\_\_\_\_

DOB: \_\_\_\_\_ Gender: \_\_\_\_\_

Primary Care Physician: \_\_\_\_\_

Requesting Provider: \_\_\_\_\_

Prov. Phone: \_\_\_\_\_ Prov. Fax: \_\_\_\_\_

Provider Address: \_\_\_\_\_

Provider NPI: \_\_\_\_\_

Contact Name: \_\_\_\_\_

Provider Signature: \_\_\_\_\_

Date: \_\_\_\_\_

### Product Information

Drug product: ☒ Pulmozyme 1 mg/mL solution

**Start date** (or date of next dose): \_\_\_\_\_

**Date of last dose** (if applicable): \_\_\_\_\_

**Dosing frequency:** \_\_\_\_\_

### Precertification Requirement

**Before this drug is covered, the patient must meet all of the following requirements for a 12-month initial authorization:**

1. Must be used for cystic fibrosis (CF)
2. Age ≥ 5 years
3. Prescribed by Pulmonologist or Infectious Disease specialist.

**For continuation, the patient must meet all of the following requirements every 12-months:**

1. Must provide FVC
2. Must provide documentation showing stable disease
3. Must provide documentation supporting decreased incidence of respiratory infections

**Note:** Authorization for indications, dosing, or a route of administration not approved by the Food and Drug Administration (FDA) or recognized in CMS-accepted compendia (e.g. DrugDex, AHFS, U.S. Pharmacopeia, and also Clinical Pharmacology for oncology indications only) require supporting evidence for coverage. Please provide two published peer-reviewed literature articles supporting the appropriateness of the drug, the dosing of the drug, or the route of administration to be used for the identified indication.

### New Request

#### Priority Health Precertification Documentation

##### A. What is the patient's diagnosis?

☐ cystic fibrosis

☐ **Other:** \_\_\_\_\_

**Rationale for use:** \_\_\_\_\_

**B. What is the prescriber's specialty?**

- ☐ Pulmonology  
☐ Infectious Disease  
☐ Other: \_\_\_\_\_
- 

**Continuation Request  
Priority Health Precertification Documentation**

**A. What is the patient's FVC?**

**FVC:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**B. Is there documentation showing stable disease?**

- ☐ Yes  
☐ No

**C. Is there documentation showing a decreased incidence of respiratory infections?**

- ☐ Yes  
☐ No